OCUL News & Events

Ocular Therapeutix (OCUL) announced that David Robinson has agreed to join the Company as Global Chief Commercial Officer. Prior to joining Ocular, Robinson served as Chief Marketing Officer, Global Ophthalmology at Merck (MRK)

Sanofi (SNY) is preparing to launch an improved bid for Ocular Therapeutix (OCUL), Investor's Business Daily's Allison Gatlin reports. Ocular CEO Pravin Dugel previously sold Iveric Bio to Astellas Pharma (ALPMY) for $5.9B in 2023, the report notes. Ocular Therapeutix is working on treatments for a number of eye diseases, including diabetic retinopathy, wet AMD and retinal vein occlusion. Shares of Ocular Therapeutix are up 2.6% to $11.36 in morning trading.

Ocular Therapeutix is up 11.7%, or $1.30 to $12.37.